BRAF and Miyoshi myopathy: In BRAF-mutated MM patients treated with TRA monotherapy vs. CombiDT, a phase 2 trial showed that trough plasma concentration of TRA above 10.6 ng/mL was associated with a better clinical efficacy [14,15], but this result was not confirmed in a phase 3 [14,16] trial.